Ability to swallow entrectinib intact

Unable or unwilling to swallow napabucasin capsules daily.

Patients must be able to swallow tablets whole

Patients must be able to swallow capsules

Patients unable to swallow capsules whole are not eligible; nasogastric or gastric (G) tube administration is not allowed

Patients must be able to swallow tablets or capsules; a patient with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligible

Patients must be able to swallow whole capsules

Patients must be able to swallow tablets

Patients must be able to swallow tablets

Ability to swallow abiraterone acetate tablets as a whole

Patients must be able to swallow intact capsules

Patients who are unable to swallow whole tablets are not eligible

Patients who are unable to swallow intact tablets are not eligible

Patients must be able to swallow intact tablets

Patients must be able to swallow intact tablets

Patients must be able to swallow intact tablets

Patients must be able to swallow intact capsules

Patients must be able to swallow intact tablets

Able to swallow capsules

Inability to swallow capsules or known gastrointestinal malabsorption

Ability to swallow tablets

Able to swallow ribociclib capsules

Patients must be able to swallow tablets

Eligible patients have a body surface area >= 0.7 m^2 AND be able to swallow whole tablets at the time of study enrollment

Patients who are unable to swallow whole tablets are not eligible

Patient must be able to swallow capsules

Subjects who are unable to swallow pills

Ability to swallow the investigational product tablets.

Participants must be able to swallow ribociclib capsules or tablets

Inability to swallow intact tablets

Able to swallow capsules

Inability or unwillingness to swallow capsules; patients with any condition that may impair the ability to swallow or absorb oral medications/investigational product including:\r\n* Any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow capsules or pills;\r\n* Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel;\r\n* Active peptic ulcer disease;\r\n* Malabsorption syndrome

Able to swallow capsules

Inability to swallow intact tablets

The subject is unable to swallow capsules.

Ability to swallow pills or capsules

Participant is unable to swallow or absorb oral tablets.

Inability to swallow capsules

Subject is unable to swallow pills

Must be able to swallow ribociclib and everolimus capsules/tablets

Inability to swallow gelatin capsules, or any medical condition that interferes with normal gastrointestinal absorption

Must be able to swallow LEE011 and everolimus capsules/tablets

Patients must have the ability to swallow tablets

Patients who are unable to swallow tablets or liquid are not eligible.

Patients must be able to swallow capsules; nasogastric or gastrostomy feeding (G) tube administration is not allowed

The participant is unable to swallow tablets that are whole (do not crush or chew or administer via nasogastric [NG]-tube)

Gastrointestinal disorder affecting absorption or the ability to swallow tablets

Patients must be able to swallow tablets (or applesauce, if part of bioavailability \crushed\ six patient cohort)

Unable or unwilling to swallow napabucasin capsules daily.

Unable or unwilling to swallow tablets as per dosing schedule

Subjects that cannot swallow tablets.

Subject is unable to swallow or absorb oral tablets normally

Ability to swallow pills/capsules

Inability to swallow capsules, since capsules cannot be crushed or broken

Unable or unwilling to swallow tablets or capsules

Patients must be able to swallow capsules

Able to swallow tablets.

Patient must be able to swallow capsules

Patients who are unable to swallow erlotinib tablets are not eligible

Patients must be able to swallow whole tablets or capsules; nasogastric or gastrostomy tube (G-tube) administration is not allowed

Patients must be able to swallow whole tablets or capsules; nasogastric or gastrostomy tube (G-tube) administration is not allowed; any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowed

Are able to swallow capsules

Participant must be able to swallow tablets or capsules. A participant with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligible.

Patients who are unable to swallow tablets or have a gastrointestinal disease that could hinder the absorption of enzalutamide.

Ability to swallow oral tablets without difficulty

Unable to swallow capsules or disease significantly affecting gastrointestinal function

Patients must be able to swallow intact tablets

Patients who are not able to swallow intact tablets are not eligible

Patients must be able to swallow intact capsules

Patients must be able to swallow capsules

Unable to swallow tablets.

Are able to swallow capsules.

Inability to swallow intact tablets

Unable to swallow or take anything orally

Unable or unwilling to swallow tablets or capsules

Inability to swallow intact tablets

Inability to swallow intact tablets

Men unable to swallow pills

Has an inability to swallow tablets or capsules

Patients who are unable to swallow pills

Able to swallow intact capsules

Inability to swallow capsules, since capsules cannot be crushed or broken

The subject is unable to swallow capsules

Unable or unwilling to swallow tablets

Able to swallow bicalutamide and ribociclib capsules/tablets.

Patient must be capable of swallowing the ruxolitinib capsules (tablets)

Be able to swallow tablets.

Must be able to swallow pills or capsules

The subject is unable to swallow tablets

Ability to swallow capsules unless enrolled in Part E

Part E: Any patient unable to swallow capsules who otherwise meet all other eligibility criteria for Part A (expansion) B, C or D

Patients must be able to swallow whole capsules; nasogastric or gastrointestinal (G)-tube administration is not allowed

Is unable to swallow capsules or malabsorption syndrome, disease or condition significantly affecting gastrointestinal function

Able to swallow capsules

Is unable to swallow capsules or malabsorption syndrome, disease or condition significantly affecting gastrointestinal function

Are able to swallow capsules and tablets.

Patients must be able to swallow AZD1775 capsules

Ability to swallow and retain capsules.

Patients must be able to swallow intact tablets; patients who cannot swallow intact tablets are not eligible

Ability to swallow capsules

Inability to swallow capsules, since capsules cannot be crushed or broken

PART 2 GROUP 1 INCLUSION CRITERIA: Subjects taking capsule formulations must be able to swallow capsules

PART 2 GROUP 2A INCLUSION CRITERIA: Subjects taking capsule formulations must be able to swallow capsules

PART 2 GROUP 3 INCLUSION CRITERIA: Subjects taking capsule formulations must be able to swallow capsules

Able to swallow the study drugs whole as tablets

Patients must be able to swallow whole tablets

Unable or unwilling to swallow tablets

Patients unable to swallow pills.

CAPMATINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules

CERITINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules

REGORAFENIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules

ENTRECTINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules

Patient has a condition that would prevent him or her from being able to swallow Toca FC tablets or absorb flucytosine.

Impaired gastrointestinal (GI) function or GI disease that may alter absorption of ceritinib or inability to swallow up to five ceritinib capsules daily; although, patients unable to swallow capsules will be allowed to participate in this study, by following the specific instructions on making a slurry of the medication

The subject is unable to swallow tablets

Patients who are unable to swallow pills/capsules are ineligible

Patients must be able to swallow intact capsules whole

Inability to swallow tablets or capsules

Patient must be able to swallow capsules

Ability to swallow pills or capsules

Subject is unable to swallow or absorb oral tablets normally

Inability or unwillingness to swallow capsules

Unable to swallow capsules

Patients with malabsorption syndrome or other condition that would interfere with intestinal absorption; patients must be able to swallow capsules

Unable to swallow tablets

Patients who cannot swallow whole tablets (i.e. medication tablets)

Unwilling or unable to swallow tablets BID

The subject is unable to swallow tablets

The subject is unable to swallow tablets

COHORTS 1 AND 2: HEALTHY VOLUNTEERS: Ability to swallow capsules or tablets

Patient must be able to swallow capsules

Capacity to swallow

Part E: Are able to swallow capsules or tablets

Patients who are unable to swallow pills

Patients who are unable to swallow oral gel capsules are not eligible

Ability to swallow medication capsules by mouth (which may include taking nilotinib mixed in apple sauce)

Participants must be able to swallow capsules

The subject must be able to swallow tablets, or receive tablets crushed and/or dispensed in water via nasogastric or orogastric tube.

Patients must be able to swallow tablets and have no significant impairment in gastrointestinal absorption

Able to swallow capsules whole (pomalidomide capsules cannot be crushed, dissolved or broken)

The subject is unable to swallow tablets

Patients must be able to swallow whole capsules

Patients must be able to swallow capsules

Patient must be able to swallow capsules

TUMOR BIOPSY SEQUENCING: Patients with gastrointestinal conditions that might predispose for drug intolerability or poor drug absorption (e.g., inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, malabsorption syndrome, and active peptic ulcer disease) are excluded; subjects with Crohn’s disease or a partial or complete small bowel obstruction are also excluded, as are any patients who cannot swallow tablets or capsules whole; tablets or capsules must not be crushed or chewed; nasogastric or gastrostomy tube (G-tube) administration is not allowed

TREATMENT: Patients with gastrointestinal conditions that might predispose for drug intolerability or poor drug absorption (e.g., inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, malabsorption syndrome, and active peptic ulcer disease) are excluded; subjects with Crohn's disease or a partial or complete small bowel obstruction are also excluded, as are any patients who cannot swallow tablets or capsules whole; tablets or capsules must not be crushed or chewed; nasogastric or G-tube administration is not allowed

Patients who are not able to swallow capsules or tablets

The subject is unable to swallow capsules or tablets

Inability to swallow lenalidomide capsules whole; capsules of 13-isotretinoin may be opened

Patients must be able to swallow capsules

Must be able to swallow ribociclib and tamoxifen capsules/tablets

Patients unable to swallow tablets or patients with malabsorption syndrome, or any other disease significantly affecting gastrointestinal function

Must be able to swallow ribociclib capsules

Subject is able to swallow capsules and is able to take or tolerate oral medications on a continuous basis

Patients must be able to swallow capsules whole

PHASE II: Patients must be able to swallow capsules whole

Known inability to swallow capsules

Patients must be able to swallow tablets whole

Patients must be able to swallow whole capsules

Patients must be able to swallow capsules whole

Patients who are unable to swallow pills

Unable or unwilling to swallow tablets BID

Patients must be able to swallow whole tablets or capsules; nasogastric or gastrostomy (G)-tube administration is not allowed; any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowed

Patients must be able to swallow capsules/tablets

Patients who are unable to swallow pills are excluded

Part C: Patients must be able to swallow intact capsules

Patients must be able to swallow whole tablets; nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewed

Patients must be able to swallow whole capsules and tolerate oral medications

Patients unable to swallow whole capsules

Able to swallow whole capsules

Patients taking the capsule formulation must be able to swallow capsules; feeding tube administration is allowed for patients receiving the oral solution (OS)

Patients must be able to take oral medications; patients must be able to swallow capsules whole without crushing or altering them in any way

are able to swallow capsules

Unable to swallow pills

Patients must have the ability to swallow tablets

Unable or unwilling to swallow tablets

Unable to swallow tablets

The subject is unable to swallow tablets

Patients must be able to swallow whole capsules

Inability to swallow capsules.

Unable to swallow capsules or disease significantly affecting gastrointestinal function

Patients must be able to swallow whole capsules

Are able to swallow capsules and tablets.

Subject is able to swallow capsules

Unable to swallow capsules or disease significantly affecting gastrointestinal function

Unable or unwilling to swallow BBI608 and/or BBI503 capsules daily

Any condition causing an inability to swallow tablets.

Unable or unwilling to swallow BBI608 capsules daily.

Must be able to swallow lenalidomide capsules

Unable or unwilling to swallow BBI608 capsules daily

Are able to swallow capsules

The subject is unable to swallow tablets

Unable to swallow capsules

Must be able to swallow ribociclib / placebo capsules/tablets

Patients must be able to swallow capsules

Inability to swallow capsules

Patients unable to swallow tablets or patients with malabsorption syndrome, or any other disease significantly affecting gastrointestinal function

Inability to swallow tablets

The subject is unable to swallow tablets

Unable to swallow tablets, or diagnosed malabsorption syndrome, or any other disease significantly affecting gastrointestinal function

Patients must be able to swallow whole capsules

Inability to swallow tablets or capsules

Inability to swallow capsules.

Able to swallow tablets

Inability to swallow tablets

Patients must be willing and able to swallow oral tablets

Patients must have the ability to swallow tablets

Inability to swallow tablets or use of a feeding tube

Patients who are unable or unwilling to swallow tablets

Unable or unwilling to swallow BBI608 capsules daily.

Able to swallow capsules

Participant is unable or unwilling to swallow tablets

Willing to take abiraterone acetate on an empty stomach; no food should be consumed at least two hours before and for at least one hour after the dose of abiraterone acetate is taken, and should be able to swallow tablets whole, without crushing/chewing tablets

Unable or unwilling to swallow BBI503 capsules daily

Unable or unwilling to swallow BBI608 capsules daily.

The subject is unable to swallow tablets

Are able to swallow tablets

Patients must be able to swallow tablets

Patients with an inability to swallow tablets or capsules

The subject is unable to swallow capsules tablets

Patients who are unable to swallow pills

The participant is unable to swallow capsules or tablets

Patients who cannot swallow capsules

Patients who are unable to swallow pills are not eligible

Patients must be able to swallow intact capsules

Inability to swallow capsules or known gastrointestinal malabsorption

Unable to swallow pills

Ability to swallow oral capsules

Are able to swallow capsules

Are able to swallow capsules or tablets

Unable or unwilling to swallow the complete daily dose of ARQ 087 capsules

Patients must be able to swallow the vorinostat capsules or have a feeding tube to allow for drug suspension

Patients who are unable to swallow tablets

Inability to swallow the HKI-272 capsules

Able to swallow capsules

Able to swallow capsules

Inability to swallow capsules

Ability to swallow tablets without difficulty;

Patients must be able to swallow tablets

Able to swallow tablets

The subject is unable to swallow tablets

Patients must be able to swallow whole capsules; capsules must not be crushed or chewed; capsules must not be opened

RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patient must be able to swallow capsules whole

NON-PROGRESSED DIPG (STRATUM 2): Patient must be able to swallow capsules whole

Known inability to swallow up to five ceritinib (LDK378) capsules daily

Ability to swallow intact palbociclib capsules and bicalutamide tablets

The subject is unable to swallow tablets

Inability to swallow oral capsules

Unable to swallow tablets, or patients with malabsorption syndrome, or any other disease significantly affecting gastrointestinal function.

Subject is unable to swallow capsules or tablets

Inability or unwillingness to swallow capsules

Patients must be able to swallow whole tablets (for MK-2206); nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewed

Able to swallow capsules and maintain adequate hydration

Patients will be excluded if they are unable to swallow capsules whole.

Unable to swallow a whole tablet or capsule.

Patients who are not able to swallow capsules or tablets

Must be able to swallow whole capsules

Ability to swallow tablets.

Unable or unwilling to swallow BBI608/placebo capsules daily.

Patients must be able to swallow capsules

Inability or unwillingness to swallow capsules

Patients must be able to swallow whole tablets; nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewed

Unable or unwilling to swallow BBI608, BBI503, or sorafenib capsules or tablets

Patients must be able to swallow tablets whole, without crushing

Patients must be able to swallow whole capsules

Patients must be able to swallow whole tablets; tablets must not be crushed or chewed

The subject is unable to swallow tablets

The subject is unable to swallow tablets

Patients must be able to swallow whole tablets and capsules

PHASE I: >= 3 years and =< 18 years of age at the time of study enrollment, if able to swallow whole capsules

PHASE II: >= 2 and =< 18 years; body surface area (BSA) >= 0.55 m^2, and able to swallow whole capsules

Inability to swallow capsules, since capsules cannot be crushed or broken

Inability to swallow tablets for everolimus arm

Patient must be able to swallow whole tablets

Patients must be able to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation

Patients must be able to swallow capsules whole; nasogastric or gastrostomy (G) tube administration is not allowed

Able to swallow whole capsules

Patients must be able to swallow tablets

Patients must be able to swallow capsules

Patients must be able to swallow tablets

Subject is able to swallow enzalutamide capsules and comply with study requirements.

Patients must be able to swallow either intact capsules or mini-tabs without chewing

Must be able to swallow tablets and capsules

Patient must have the ability to swallow multiple capsules

Participants who are unable to swallow pills

Able to swallow capsules

Inability to swallow tablets

Inability to swallow tablets

Able to swallow oral capsules without difficulty.

Able to swallow capsules

Ability to swallow oral tablets

Ability to swallow and tolerate oral tablets

GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Patients must be able to swallow intact capsules/tablets, unless otherwise specified in the subprotocol to which they are assigned

Patient must be able to swallow capsules (phase III only)

Subjects must be able to swallow capsules/tablets

Inability or unwillingness to swallow capsules

Patients must be able to swallow whole capsules

Unable or unwilling to swallow BBI608 capsules daily

Subjects that are unable to swallow a tablet/pill

Patients must be able to swallow whole tablets or capsules; nasogastric or g-tube administration is not allowed; any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowed

Unable to swallow capsules or disease significantly affecting gastrointestinal function